Abstract
Murine double minute-2 (MDM2) is an oncoprotein that inhibits p53 tumor-suppressor protein. Overexpression of MDM2 gene encoding a nuclear protein was shown to enhance the tumorigenic potential of cells. We made a serological survey of anti-MDM2 antibodies in sera of patients with cancers and healthy donors using EIA with synthesized MDM2 antigen. Circulating antibodies against MDM2 protein were detected in sera from patients with breast cancer, colon cancer, gastric cancer and lung cancer. In gastric cancers, immunohistochemical expression of MDM2 and p53 were observed. From results of the serological detection, we suggested clinical usefulness of circulating autoantibody to MDM2 as a tumor marker for male patients with colon cancer, gastric cancer and lung cancer and female patient with breast cancer, especially early breast cancer.
